67 results
This study has been transitioned to CTIS with ID 2024-512676-36-00 check the CTIS register for the current data. * To decrease mortality in MS-LCH by an early switch of patients with risk organ involvement, who do not respond to front-line therapy,…
This study has been transitioned to CTIS with ID 2024-511348-25-00 check the CTIS register for the current data. Part 1: To evaluate the efficacy and safety of imetelstat in transfusion dependent subjects with low or intermediate-1 risk MDS that is…
Primary: Part 1: Safety and tolerability. Determine the MTD and/or RP2D of MAK683.Part 2: Anti-tumor activity of MAK683.Secondary: Part 1: Anti-tumor activity. Pharmacodynamics (PD). Pharmacokinetics (PK).Part 2: Safety and tolerability. PK, PD.
Primary Objectives:* Identify the maximum tolerated dose (MTD) of oprozomib formulations in combination with pomalidomide and dexamethasone (OPomd) in subjects with relapsed or refractory multiple myeloma* Evaluate the safety and tolerability of the…
Primary Objective:To evaluate RBC transfusion independence in the 2 treatment arms (oral azacitidine plus best supportive care versus placebo plus best supportive care) in subjects with RBC transfusion-dependent anemia and thrombocytopenia (platelet…
Primary Objective: Test the capacity of drug candidates to specifically inhibit the signalling pathways they target in human blood cells in vitro in the setting of human whole blood.Secondary Objective(s): Test whether drug candidates exert…
Evaluation of the effect of daratumumab in combination with ATRA in patients with relapsed/refractory multiple myeloma